Hólyagrák: nyitott vizsgálatok itt: Németország
38 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. nov. 10.. Ask the study team whether a trial fits you.
3. fázisToborzás még nem indultResearch participation
A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy
- Where
- Bonn, Magdeburg, Mannheim
- Age
- 18 év and over
- People
- 142 worldwide
- Run by
- Systimmune Inc.
See details and how to join2026-527617-29-00EU 2026-527617-29-00Regiszter frissítve: 2026-11-06
No phaseToborozResearch participation
Registry Platform Urologic Cancer
- Where
- Multiple Locations
- Age
- 18 év and over
- People
- 2230
- Run by
- iOMEDICO AG
See details and how to joinNCT03374267Regiszter frissítve: 2026-11-05
1. fázisToborozTrial-stage medicine
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Where
- Bonn, München, Tübingen
- Age
- 18 év and over
- People
- 677 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05614739EU 2022-502755-59-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- Where
- Berlin, Braunschweig, Cologne, Dresden, Frankfurt am Main, Hamburg, Herne, Jena, München, Straubing, Stuttgart
- Age
- 18 év and over
- People
- 641 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06319820Regiszter frissítve: 2026-11-03
3. fázisToborozTrial-stage medicine
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
- Where
- Cologne, Herne, Leverkusen, Mannheim, Nuertingen, Regensburg
- Age
- 18 év and over
- People
- 220 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06919965EU 2024-519493-39-00Regiszter frissítve: 2026-11-03
3. fázisToborozTrial-stage medicine
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
- Where
- Berlin, Dresden, Duesseldorf, Hamburg, Heidelberg, Herne, Muenster, Regensburg, Stuttgart, Ulm
- Age
- 18 év and over
- People
- 590 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07419295EU 2024-520014-22-00Regiszter frissítve: 2026-11-03
2. fázisToborozTrial-stage medicine
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
- Where
- Herne
- Age
- 18 év and over
- People
- 240 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07475806Regiszter frissítve: 2026-11-02
2/3. fázisToborozResearch participation
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.
- Where
- Aachen, Cologne, Dresden, Essen, Goettingen, Halle Saale, Hamburg, Herne, Jena, Kiel, Luebeck, Lutherstadt Eisleben, Mannheim, Munich, Nuertingen, Stuttgart, Tuebingen, Ulm
- Age
- 18 év and over
- People
- 343 worldwide
- Run by
- Daiichi Sankyo Inc.
See details and how to join2024-516906-47-00EU 2024-516906-47-00Regiszter frissítve: 2026-10-29
No phaseToborozResearch participation
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
- Where
- Hamburg, Herne, München, Ulm
- Age
- 18 év and over
- People
- 500 worldwide
- Run by
- Photocure
See details and how to joinNCT07144319Regiszter frissítve: 2026-10-29
3. fázisToborozTrial-stage medicine
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- Where
- Dresden, Duesseldorf, Hamburg, Heidelberg, Herne, Jena, Luebeck, Muenster, Ulm
- Age
- 18 év and over
- People
- 390 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566156EU 2026-525612-34-00Regiszter frissítve: 2026-10-28
2. fázisToborozTrial-stage medicine
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Frankfurt
- Age
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478EU 2023-507641-29-00Regiszter frissítve: 2026-10-26
1/2. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Berlin, Dresden, Heidelberg, Heilbronn, Leipzig, Mainz, Muenster
- Age
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064EU 2023-509632-26-00Regiszter frissítve: 2026-10-26
1. fázisToborzás még nem indultResearch participation
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Cologne, Essen
- Age
- 18 év and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00EU 2024-518348-19-00Regiszter frissítve: 2026-10-21
1/2. fázisToborozTrial-stage medicine
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
- Where
- Bochum, München, Ulm
- Age
- 18 év and over
- People
- 245 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07186842EU 2025-522613-26-00Regiszter frissítve: 2026-10-15
No phaseToborozResearch participation
Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for Urothelial Carcinoma
- Where
- Munich
- Age
- 18 év and over
- People
- 79
- Run by
- Comprehensive Cancer Center Munich (CCCM)
See details and how to joinNCT07870577Regiszter frissítve: 2026-10-13
3. fázisToborozTrial-stage medicine
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Where
- Bad Saarow, Bielefeld, Bonn, Cologne, Dresden, Duisburg, Düsseldorf, Erlangen, Essen, Frankfurt, Freiburg im Breisgau, Greifswald, Hamburg, Heidelberg, Homburg, Koblenz, Lübeck, Munich, Münster, Nuremberg, Nürtingen, Rostock, Tübingen, Ulm, Würzburg
- Age
- 18 év and over
- People
- 450 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218380EU 2025-522855-25-00Regiszter frissítve: 2026-10-07
No phaseToborozResearch participation
Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)
- Where
- Munich
- Age
- 18 év and over
- People
- 500
- Run by
- LMU Klinikum
See details and how to joinNCT07855926Regiszter frissítve: 2026-10-02
1. fázisToborozTrial-stage medicine
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Essen, Heidelberg, Herne, Jena, Nuertingen, Tuebingen
- Age
- 18 év and over
- People
- 1394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483EU 2023-510061-10-00Regiszter frissítve: 2026-10-01
2. fázisToborozTrial-stage medicine
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- Where
- Halle Saale, Herne, Jena, Munich, Stuttgart
- Age
- 18 év and over
- People
- 308 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06833073EU 2024-517335-46-00Regiszter frissítve: 2026-10-01
3. fázisToborozResearch participation
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.
- Where
- Bochum, Bonn, Dresden, Duisburg, Frankfurt am Main, Giessen, Hamburg, Hanover, Herne, Magdeburg, Mannheim, Mettmann, Muenster, Nuertingen, Nuremberg, Regensburg, Rostock, Stuttgart, Tuebingen, Ulm
- Age
- 18 év to 64 év
- People
- 262 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-525030-57-00EU 2025-525030-57-00Regiszter frissítve: 2026-09-28
2. fázisToborozResearch participation
A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.
- Where
- Berlin, Dresden, Duesseldorf, Gera, Goettingen, Herne, Luebeck, Muenster, Munich, Potsdam, Regensburg, Stuttgart
- Age
- 18 év and over
- People
- 88 worldwide
- Run by
- Astellas Pharma Global Development Inc.
See details and how to join2025-524488-18-00EU 2025-524488-18-00Regiszter frissítve: 2026-09-21
No phaseToborozResearch participation
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Where
- Hamburg, Heilbronn, Munich
- Age
- 18 év and over
- People
- 2285 worldwide
- Run by
- Guardant Health, Inc.
See details and how to joinNCT05059444Regiszter frissítve: 2026-09-14
3. fázisToborozResearch participation
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
- Where
- Guetersloh, Muenster, Oldenburg
- Age
- 18 év and over
- People
- 87 worldwide
- Run by
- Astrazeneca AB
See details and how to joinNCT05303532EU 2023-507337-22-00Regiszter frissítve: 2026-09-08
2/3. fázisToborozTrial-stage medicine
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- Where
- Eisleben Lutherstadt, Herne, Nürtingen, Stuttgart
- Age
- 18 év and over
- People
- 630 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07129993Regiszter frissítve: 2026-08-20
1/2. fázisToborozTrial-stage medicine
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Dresden, Essen, Frankfurt, Ulm, Würzburg
- Age
- 18 év and over
- People
- 1109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709Regiszter frissítve: 2026-08-17
Minden vizsgálat (Hólyagrák) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.